PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE

Author(s):
Ason, B.; Hoorn, J.W.A. van der; Chan, J.; Lee, E.; Pieterman, E.J.; Nguyen, K.K.; ; Shetterly, S.; Tang, J.; Yeh, W.C.; Schwarz, M.; Jukema, J.W. (0000-0002-3246-8359); Scott, R.; Wasserman, S.M.; Princen, H.M.G.; Jackson, S.
Published
2014
Publication type
Article / Letter to editor
apolipoprotein Eanti-proprotein convertase subtilisin/kexin type 9 antibodylow density lipoprotein receptorproprotein convertase subtilisin/kexin type 9
Date issued
2014-11-30
Language
English
Is part of
Journal of Lipid Research (2014), Vol. 55, no. 11, p. 2370-2379
hdl
1887/103264
doi
10.1194/jlr.M053207